Prosecution Insights
Last updated: April 19, 2026
Application No. 17/779,332

Metal-Organic Material Extrudates, Methods of Making, and Methods of Use

Non-Final OA §103
Filed
May 24, 2022
Examiner
PEPITONE, MICHAEL F
Art Unit
1767
Tech Center
1700 — Chemical & Materials Engineering
Assignee
ExxonMobil
OA Round
3 (Non-Final)
74%
Grant Probability
Favorable
3-4
OA Rounds
3y 2m
To Grant
96%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allow Rate
865 granted / 1165 resolved
+9.2% vs TC avg
Strong +22% interview lift
Without
With
+22.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
52 currently pending
Career history
1217
Total Applications
across all art units

Statute-Specific Performance

§101
0.2%
-39.8% vs TC avg
§103
40.9%
+0.9% vs TC avg
§102
24.8%
-15.2% vs TC avg
§112
19.8%
-20.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1165 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 2/2/26 has been entered. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1, 3-8, 18-20, and 29-30 is/are rejected under 35 U.S.C. 103 as being unpatentable over Bazer-Bachi et al. (WO 2014/135783) (English machine translation for citation) [IDS 5/24/22] in view of Stein et al. (US 2010/0126344), when taken with Bazer-Bachi, D.; Assié, L.; Lecocq, V.; Harbuzaru, B.; Falk, V. Powder Technol. 2014, 255, 52. [IDS 5/24/22]. Regarding claims 1, 3-8 and 29-30: Bazer-Bachi et al. (WO ‘783) discloses organic-inorganic materials containing a polymeric binder [abstract], wherein Example 3 [Ex. 3; 0082-0093; Table 2, Ex. 3] prepares a composition containing 8.25 wt% polyvinylpyrrolidone (PVP) and 91.75 wt% ZIF-8 (Zn2+/2-methyl imidazole). The composition was extruded into a rod [Ex. 3; 0082-0093; Table 2, Ex. 3]. Bazer-Bachi et al. (WO ‘783) does not disclose a polyvinyl ester as the binder. However Stein et al. (US ‘344) discloses metal organic frameworks [abstract; 0186-0195] comprising polymeric binders [0084-0109] such as polyvinyl acetate [0093; 0107; 0109; 0126], polyvinyl pyrrolidone [0126], polyvinyl alcohol, and partially hydrolyzed polyvinyl acetate [0126]. Bazer-Bachi et al. (WO ‘783) and Stein et al. (US ‘344) are analogous art because they are concerned with a similar technical difficulty, namely the preparation of compositions containing metal organic frameworks and polymeric binders. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have combined polyvinyl acetate, polyvinyl alcohol, and/or partially hydrolyzed polyvinyl acetate, as taught by Stein et al. (US ‘344) in the invention of Bazer-Bachi et al. (WO ‘783), and would have been motivated to do so since Stein et al. (US ‘344) suggests polyvinyl pyrrolidone, polyvinyl acetate, polyvinyl alcohol, and/or partially hydrolyzed polyvinyl acetate as equivalent polymeric binders [0084; 0126] [see also MPEP 2144.06]. The claimed effects and physical properties, i.e. a bulk crush strength of about 6 lb-force or greater [instant claim 1], would implicitly be achieved, as “Products of identical chemical composition can not have mutually exclusive properties.” A chemical composition and its properties are inseparable. Therefore, if the prior art teaches the identical chemical structure, the properties applicant discloses and/or claims are necessarily present. In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990) [see MPEP 2112.01]. Bazer-Bachi et al. (Powder Technol. 2014, 255, 52) provides evidence for ZIF-8 as Zn2+/2-methyl imidazole [§2.1] Regarding claims 18-20: Bazer-Bachi et al. (WO ‘783) discloses the basic claimed composition [as set forth above with respect to claim 1]. The claimed effects and physical properties, i.e. a comparative BET surface area of from about 70% to about 100% [instant claim 18]; a porosity of from about 70% to about 100% of the metal-organic framework material [instant claim 19]; a pore size of from about 2 Å to about 25 Å [instant claim 20], would implicitly be achieved, as “Products of identical chemical composition can not have mutually exclusive properties.” A chemical composition and its properties are inseparable. Therefore, if the prior art teaches the identical chemical structure, the properties applicant discloses and/or claims are necessarily present. In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990) [see MPEP 2112.01]. Response to Arguments Applicant's arguments filed 2/2/26 have been fully considered but they are not persuasive. The rejection of claims based upon Bazer-Bachi et al. (WO 2014/135783) and Stein et al. (US 2010/0126344) is maintained. Bazer-Bachi et al. (WO 2014/135783) (English machine translation for citation) was relied on for disclosing organic-inorganic materials containing a polymeric binder [abstract], wherein Example 3 [Ex. 3; 0082-0093; Table 2, Ex. 3] prepares a composition containing 8.25 wt% polyvinylpyrrolidone (PVP) and 91.75 wt% ZIF-8 (Zn2+/2-methyl imidazole). The composition was extruded into a rod [Ex. 3; 0082-0093; Table 2, Ex. 3]. Stein et al. (US 2010/0126344) was relied on for disclosing metal organic frameworks [abstract; 0186-0195] comprising polymeric binders [0084-0109] such as polyvinyl acetate [0093; 0107; 0109; 0126], polyvinyl pyrrolidone [0126], polyvinyl alcohol, and partially hydrolyzed polyvinyl acetate [0126]. While Table 4 {i.e. polyvinyl acetate (PVAc) and polyvinyl alcohol (PVA)} appears to provide unexpected results over Tables 1-2 {i.e. PVP or Methocel (hydroxypropyl methyl cellulose)}, however, the examples in Table 4 represent specific compositions and are not commensurate in scope with the breadth of compositions included in claim 1. It is unclear if the combination and the specific amounts of polyvinyl acetate and polyvinyl alcohol provide the unexpected results, or if any amount of polyvinyl acetate and polyvinyl alcohol yield comparable results. Additionally, the specific polyvinyl ester (polyvinyl acetate) is of narrower scope than the broad genus of polyvinyl ester listed in claim 1. As the data in Table 4 was obtained from compositions of narrower scope of claim 1, it is not possible for the examiner to conclude the data from Table 4 represents unexpected results over the prior art of record [see also MPEP 716.01(c), 716.02(d), 2145; In re Lindner, 457 F.2d 506, 509, 173 USPQ 356, 359 (CCPA 1972); In re Lindner, 457 F.2d 506, 508, 173 USPQ 356, 358 (CCPA 1972)]. Additionally, to establish unexpected results over a claimed range, applicants should compare a sufficient number of tests both inside and outside the claimed range to show the criticality of the claimed range. In re Hill, 284 F.2d 955, 128 USPQ 197 (CCPA 1960) [see MPEP 716.02(d)]. See also In re Lindner, 457 F.2d 506, 509, 173 USPQ 356, 359 (CCPA 1972). Whether the unexpected results are the result of unexpectedly improved results or a property not taught by the prior art, the “objective evidence of non-obviousness must be commensurate in scope with the claims which the evidence is offered to support.” In other words, the showing of unexpected results must be reviewed to see if the results occur over the entire claimed range. In re Clemens, 622 F.2d 1029, 1036, 206 USPQ 289, 296 (CCPA 1980) [See MPEP 716.02(d)]. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICHAEL F PEPITONE whose telephone number is (571)270-3299. The examiner can normally be reached on 7:00 AM - 3:30 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Mark Eashoo can be reached on 571-272-1197. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MICHAEL F PEPITONE/Primary Examiner, Art Unit 1767
Read full office action

Prosecution Timeline

May 24, 2022
Application Filed
May 31, 2025
Non-Final Rejection — §103
Aug 25, 2025
Response Filed
Nov 29, 2025
Final Rejection — §103
Feb 02, 2026
Request for Continued Examination
Feb 04, 2026
Response after Non-Final Action
Feb 21, 2026
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600875
OIL-BASED INK COMPOSITION FOR BALLPOINT PENS AND BALLPOINT PEN EMPLOYING THE SAME
2y 5m to grant Granted Apr 14, 2026
Patent 12595370
POLYMERIZABLE ABSORBERS OF UV AND HIGH ENERGY VISIBLE LIGHT
2y 5m to grant Granted Apr 07, 2026
Patent 12595371
CONTACT LENS WITH IMPROVED VISION BREAK-UP TIME
2y 5m to grant Granted Apr 07, 2026
Patent 12589055
DENTAL COMPOSITION
2y 5m to grant Granted Mar 31, 2026
Patent 12584027
CURABLE ORGANOPOLYSILOXANE COMPOSITION, AND OPTICAL MEMBER FORMED FROM CURED PRODUCT OF SAME
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
74%
Grant Probability
96%
With Interview (+22.2%)
3y 2m
Median Time to Grant
High
PTA Risk
Based on 1165 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month